Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek Subbiah

Showing results (331-340 of 487) with videos related to

Pageof 49
Sort By:
JCO Precision Oncology|February 9, 2022
Phase I Trial of Dabrafenib and Pazopanib in <i>BRAF</i> Mutated Advanced MalignanciesSigurdis Haraldsdottir, Filip Janku, Ming Poi, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 19, 2018
Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With ImmunotherapyChristine M Parseghian, Madhavi Patnana, Priya Bhosale, et al.
Oncotarget|February 9, 2013
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trialsIshwaria M Subbiah, Vivek Subbiah, Apostolia M Tsimberidou, et al.
Cancers|September 19, 2020
Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical TrialsTimothy A Lin, Clifton David Fuller, Vivek Verma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2022
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II StudyVivek Subbiah, Irene Braña, Alessandra Longhi, et al.
Leukemia & Lymphoma|November 10, 2017
Myeloid/lymphoid neoplasms with FGFR1 rearrangementPaolo Strati, Guilin Tang, Dzifa Y Duose, et al.
Oncotarget|October 4, 2018
Outcome analysis of Phase I trial patients with metastatic <i>KRAS</i> and/or <i>TP53</i> mutant non-small cell lung cancerYudong Wang, Zhijie Wang, Sarina Piha-Paul, et al.
NPJ Precision Oncology|February 21, 2023
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) studyBlessie Elizabeth Nelson, Jason Roszik, Filip Janku, et al.
Oncotargets and Therapy|May 17, 2021
A Phase I Trial of the MET/<i>ALK/ROS1</i> Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid MalignanciesSarina A Piha-Paul, Ecaterina E Dumbrava, Binoj C Nair, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2019
Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating <i>RET</i> Alterations and Oncogenic Signaling Pathway AberrationsThereasa A Rich, Karen L Reckamp, Young Kwang Chae, et al.
Pageof 49

Showing results (331-340 of 487) with videos related to

Sort By:
Pageof 49
JCO Precision Oncology|February 9, 2022
Phase I Trial of Dabrafenib and Pazopanib in <i>BRAF</i> Mutated Advanced MalignanciesSigurdis Haraldsdottir, Filip Janku, Ming Poi, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 19, 2018
Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With ImmunotherapyChristine M Parseghian, Madhavi Patnana, Priya Bhosale, et al.
Oncotarget|February 9, 2013
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trialsIshwaria M Subbiah, Vivek Subbiah, Apostolia M Tsimberidou, et al.
Cancers|September 19, 2020
Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical TrialsTimothy A Lin, Clifton David Fuller, Vivek Verma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2022
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II StudyVivek Subbiah, Irene Braña, Alessandra Longhi, et al.
Leukemia & Lymphoma|November 10, 2017
Myeloid/lymphoid neoplasms with FGFR1 rearrangementPaolo Strati, Guilin Tang, Dzifa Y Duose, et al.
Oncotarget|October 4, 2018
Outcome analysis of Phase I trial patients with metastatic <i>KRAS</i> and/or <i>TP53</i> mutant non-small cell lung cancerYudong Wang, Zhijie Wang, Sarina Piha-Paul, et al.
NPJ Precision Oncology|February 21, 2023
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) studyBlessie Elizabeth Nelson, Jason Roszik, Filip Janku, et al.
Oncotargets and Therapy|May 17, 2021
A Phase I Trial of the MET/<i>ALK/ROS1</i> Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid MalignanciesSarina A Piha-Paul, Ecaterina E Dumbrava, Binoj C Nair, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2019
Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating <i>RET</i> Alterations and Oncogenic Signaling Pathway AberrationsThereasa A Rich, Karen L Reckamp, Young Kwang Chae, et al.
Pageof 49